AOD-9604 vs MOTS-C — Two Distinct Metabolic Peptides
AOD-9604 and MOTS-C both show up in fat-loss and metabolic research, so they get compared — but unlike some “versus” pairs, these are two genuinely different compounds that work through different mechanisms. This page lays out what each actually is, how they differ, and which research question each fits.
AOD-9604: a synthetic fragment of growth hormone (hGH 176-191), studied for selective fat loss / lipolysis.
MOTS-C: a mitochondrial-derived peptide (encoded in mtDNA), studied for insulin sensitivity and metabolic homeostasis as an “exercise mimetic.”
Bottom line up front: different compounds, different mechanisms — not interchangeable, and not a rigged “which is better” contest. Both are preclinical-stage and research-use only.
Why these two get compared
Both are peptides that touch fat and energy metabolism, so they end up on the same shortlists. But they come from completely different places. AOD-9604 is a lab-made fragment of human growth hormone, engineered to isolate the hormone's fat-metabolism (lipolytic) action while leaving out its growth and blood-sugar effects.
MOTS-C is something categorically different: a peptide encoded in mitochondrial DNA that your own mitochondria produce. Rather than acting like a fat-burning hormone fragment, it works upstream on cellular energy sensing — activating AMPK and improving insulin sensitivity, which is why it is described as an “exercise mimetic.”
So the honest comparison isn't “which fat-loss peptide wins” — it's two different tools aimed at overlapping-but-distinct metabolic questions, both still early in the evidence.
| AOD-9604 | MOTS-C | |
|---|---|---|
| What it is | Synthetic fragment of human growth hormone — the hGH 176-191 C-terminal region | Mitochondrial-derived peptide (MDP) encoded in mitochondrial DNA (12S rRNA region); 16 amino acids |
| Origin | Lab-synthesized; modeled on the fat-metabolism (lipolytic) domain of hGH | Naturally occurring — produced by your own mitochondria |
| Mechanism | Stimulates lipolysis / fat oxidation, mimicking hGH's effect on fat metabolism — reportedly without hGH's growth (IGF-1) or blood-sugar effects | Activates AMPK and regulates metabolic homeostasis / insulin sensitivity — behaves as an “exercise mimetic” |
| Primary research question | Selective fat loss / lipolysis | Insulin sensitivity, metabolic homeostasis, exercise-mimetic and mitochondrial/longevity biology |
| Evidence stage | Largely preclinical; human fat-loss trials were underwhelming — Phase 2 development was discontinued (2007) | Early — strong preclinical foundation (Lee et al., Cell Metab 2015); human/Phase 1 work only beginning |
| FDA status | Not FDA-approved; FDA declined the 503A Bulks List (Dec 2024) | Not FDA-approved; research-use only |
| WADA | Prohibited | Not specifically named on the prohibited list (status uncertain) |
| Route (research) | Subcutaneous injection | Subcutaneous injection |
Which fits which research question?
Both are research-use-only and neither is FDA-approved. Because the mechanisms differ, the choice is about the question you're studying, not a ranking.
Studying selective fat loss / lipolysis
AOD-9604 is the more direct mechanistic match — it was purpose-built as a lipolytic fragment of growth hormone. Temper expectations, though: its preclinical fat-oxidation results did not carry over into successful human weight-loss trials, and Phase 2 development was discontinued. It is a mechanism worth studying, not a proven fat-loss agent.
Studying insulin sensitivity, metabolic homeostasis, or exercise-mimetic biology
MOTS-C is the relevant tool. Its landmark Cell Metabolism work showed it improves metabolic homeostasis and insulin sensitivity via AMPK, positioning it as an exercise-mimetic and mitochondrial/longevity research compound rather than a direct fat-burner. The human evidence is early, so treat findings as preliminary.
Both together
Because they hit different pathways, they are sometimes combined — sold as a AOD-9604 + MOTS-c blend. There is no established combination protocol and the human data for each is limited, so any combined use is exploratory and research-use only.
Bottom Line
AOD-9604 and MOTS-C are two distinct metabolic peptides, not variants of one another. AOD-9604 is a synthetic growth-hormone fragment aimed at lipolysis; its mechanism is direct but its human fat-loss evidence is weak (Phase 2 discontinued). MOTS-C is a mitochondrial-derived peptide aimed at AMPK-driven metabolic homeostasis and insulin sensitivity, with a strong preclinical base but only early human data. Pick by research question, not by a “winner” — and note both are preclinical-stage, not FDA-approved, and research-use only.
FAQ
Are AOD-9604 and MOTS-C the same?
No — they are genuinely different compounds. AOD-9604 is a synthetic fragment of human growth hormone (the hGH 176-191 region), while MOTS-C is a mitochondrial-derived peptide encoded in mitochondrial DNA. Different origins, different structures, and different mechanisms. They overlap only in that both are studied in a metabolic context.
Do they work the same way?
No. AOD-9604 stimulates lipolysis (fat breakdown) and fat oxidation, modeled on the fat-metabolism domain of growth hormone — reportedly without hGH's growth or blood-sugar effects. MOTS-C works upstream on cellular energy metabolism, activating AMPK and improving insulin sensitivity as an “exercise mimetic.” Overlapping interest (metabolism), different pathways.
Which is better for fat-loss research?
There isn't a clean winner. AOD-9604 was purpose-built as a lipolytic fragment, so it is the more direct fat-loss mechanism on paper — but its human fat-loss trials were disappointing and Phase 2 development was discontinued. MOTS-C targets metabolic regulation and insulin sensitivity more than direct fat-burning, with promising but early evidence. The right choice depends on the exact research question, not a ranking.
Are either AOD-9604 or MOTS-C FDA-approved?
No. Neither is FDA-approved. AOD-9604's Phase 2 development was discontinued in 2007 and the FDA declined to add it to the 503A Bulks List (Dec 2024); it is also WADA-prohibited. MOTS-C is research-use-only with human/Phase 1 work only beginning. Both are sold research-use-only.
Can they be studied together?
They act through different pathways (lipolysis vs AMPK/metabolic homeostasis), so a researcher might study them for complementary metabolic questions — and they are sold together as a combined AOD-9604 + MOTS-c blend. That said, there is no established combination protocol, and human evidence for either compound is limited. Research-use only.
References
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. https://pubmed.ncbi.nlm.nih.gov/11146367/
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. https://pubmed.ncbi.nlm.nih.gov/11673763/
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9905433/
For educational and research purposes only. Not medical advice. Not for human use.
Have a question about AOD-9604 vs MOTS-C — Two Distinct Metabolic Peptides? Send us an email →